Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer

Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, Kitchener HC, Teschendorff AE, Widschwendter M

. 2012 ; 8 (2) : .

Jazyk angličtina Země Spojené státy americké

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14070323

Aberrant DNA methylation is an important cancer hallmark, yet the dynamics of DNA methylation changes in human carcinogenesis remain largely unexplored. Moreover, the role of DNA methylation for prediction of clinical outcome is still uncertain and confined to specific cancers. Here we perform the most comprehensive study of DNA methylation changes throughout human carcinogenesis, analysing 27,578 CpGs in each of 1,475 samples, ranging from normal cells in advance of non-invasive neoplastic transformation to non-invasive and invasive cancers and metastatic tissue. We demonstrate that hypermethylation at stem cell PolyComb Group Target genes (PCGTs) occurs in cytologically normal cells three years in advance of the first morphological neoplastic changes, while hypomethylation occurs preferentially at CpGs which are heavily Methylated in Embryonic Stem Cells (MESCs) and increases significantly with cancer invasion in both the epithelial and stromal tumour compartments. In contrast to PCGT hypermethylation, MESC hypomethylation progresses significantly from primary to metastatic cancer and defines a poor prognostic signature in four different gynaecological cancers. Finally, we associate expression of TET enzymes, which are involved in active DNA demethylation, to MESC hypomethylation in cancer. These findings have major implications for cancer and embryonic stem cell biology and establish the importance of systemic DNA hypomethylation for predicting prognosis in a wide range of different cancers.

Citace poskytuje Crossref.org

Erratum v: PLoS Genet. 2012 Mar;8(3). doi: 10.1371/annotation/35f168f3-c509-4b4f-b245-f6682325838e.

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc14070323
003      
CZ-PrNML
005      
20141002092353.0
007      
ta
008      
140904s2012 xxu d f 000 0eng||
009      
AR
024    7_
$a 10.1371/journal.pgen.1002517 $2 doi
035    __
$a (PubMed)22346766
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zhuang, Joanna $u Department of Women's Cancer, University College London Elizabeth Garrett Anderson Institute for Women's Health, London, United Kingdom; Statistical Genomics Group, University College London Cancer Institute, London, United Kingdom
245    14
$a The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer / $c Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, Kitchener HC, Teschendorff AE, Widschwendter M
500    __
$a Erratum v: PLoS Genet. 2012 Mar;8(3). doi: 10.1371/annotation/35f168f3-c509-4b4f-b245-f6682325838e.
504    __
$a Literatura
520    9_
$a Aberrant DNA methylation is an important cancer hallmark, yet the dynamics of DNA methylation changes in human carcinogenesis remain largely unexplored. Moreover, the role of DNA methylation for prediction of clinical outcome is still uncertain and confined to specific cancers. Here we perform the most comprehensive study of DNA methylation changes throughout human carcinogenesis, analysing 27,578 CpGs in each of 1,475 samples, ranging from normal cells in advance of non-invasive neoplastic transformation to non-invasive and invasive cancers and metastatic tissue. We demonstrate that hypermethylation at stem cell PolyComb Group Target genes (PCGTs) occurs in cytologically normal cells three years in advance of the first morphological neoplastic changes, while hypomethylation occurs preferentially at CpGs which are heavily Methylated in Embryonic Stem Cells (MESCs) and increases significantly with cancer invasion in both the epithelial and stromal tumour compartments. In contrast to PCGT hypermethylation, MESC hypomethylation progresses significantly from primary to metastatic cancer and defines a poor prognostic signature in four different gynaecological cancers. Finally, we associate expression of TET enzymes, which are involved in active DNA demethylation, to MESC hypomethylation in cancer. These findings have major implications for cancer and embryonic stem cell biology and establish the importance of systemic DNA hypomethylation for predicting prognosis in a wide range of different cancers.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a nádorová transformace buněk $x genetika $7 D002471
650    _2
$a CpG ostrůvky $x genetika $7 D018899
650    12
$a metylace DNA $x genetika $7 D019175
650    _2
$a DNA vazebné proteiny $x genetika $7 D004268
650    12
$a embryonální kmenové buňky $x cytologie $x metabolismus $7 D053595
650    _2
$a epigeneze genetická $7 D044127
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a hematopoetické kmenové buňky $x cytologie $x metabolismus $7 D006412
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory $x genetika $x metabolismus $7 D009369
650    12
$a nádorové kmenové buňky $x cytologie $x metabolismus $7 D014411
650    _2
$a polycomb proteiny $7 D063146
650    12
$a prognóza $7 D011379
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a protoonkogenní proteiny $x genetika $7 D011518
650    12
$a represorové proteiny $x genetika $x metabolismus $7 D012097
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jones, Allison $u Department of Women's Cancer, University College London Elizabeth Garrett Anderson Institute for Women's Health, London, United Kingdom
700    1_
$a Lee, Shih-Han $u Department of Women's Cancer, University College London Elizabeth Garrett Anderson Institute for Women's Health, London, United Kingdom
700    1_
$a Ng, Ester $u Statistical Genomics Group, University College London Cancer Institute, London, United Kingdom
700    1_
$a Fiegl, Heidi $u Department of Gynaecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria
700    1_
$a Zikán, Michal, $d 1976- $7 xx0096708 $u Oncogynecologic Center, Department of Obstetrics and Gynaecology, Charles University Prague-First Faculty of Medicine and General Faculty Hospital, Prague, Czech Republic
700    1_
$a Cibula, David, $d 1968- $7 jo20000074072 $u Oncogynecologic Center, Department of Obstetrics and Gynaecology, Charles University Prague-First Faculty of Medicine and General Faculty Hospital, Prague, Czech Republic
700    1_
$a Sargent, Alexandra $u School of Cancer and Imaging Science, Manchester Academie Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
700    1_
$a Salvesen, Helga B. $u Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway
700    1_
$a Jacobs, Ian J. $u Department of Women's Cancer, University College London Elizabeth Garrett Anderson Institute for Women's Health, London, United Kingdom; School of Cancer and Imaging Science, Manchester Academie Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
700    1_
$a Kitchener, Henry C. $u School of Cancer and Imaging Science, Manchester Academie Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
700    1_
$a Widschwendter, Martin $u Statistical Genomics Group, University College London Cancer Institute, London, United Kingdom
700    1_
$a Teschendorff, Andrew E. $u Department of Women's Cancer, University College London Elizabeth Garrett Anderson Institute for Women's Health, London, United Kingdom
773    0_
$t PLoS genetics $x 1553-7390 $g Roč. 8, č. 2 (2012) $w MED00008920
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20140904145750 $b ABA008
991    __
$a 20141002092727 $b ABA008
999    __
$a ok $b bmc $g 1038102 $s 869176
BAS    __
$a 3
BMC    __
$a 2012 $b 8 $c 2 $x MED00008920 $i 1553-7390 $m PLoS genetics $n PLoS Genet
LZP    __
$a 2014-09/gvbo
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace